

MRTX1133 formic Biochemical | MRTX1133 biochemical

MRTX1133 formic

CATALOG #
AAA227263


PRODUCT SYNONYMS

MRTX1133 formic; MRTX1133 biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	MRTX1133 demonstrates dose-dependent inhibition of the KRAS pathway tumor regression in G12D mutant tumor models[2].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
BM-1197, CAS 1391107-89-3



Structure
BM-1197, CAS 1391107-89-3

ADDITIONAL INFORMATION

Related Product Information for MRTX1133 biochemical	MRTX1133 is a highly selective, first-in-class inhibitor of KRAS G12D. MRTX1133 targets the KRAS G12D protein in both active and inactive states. MRTX1133 selectively inhibits KRAS G12D mutant, but not KRAS wild-type, tumor cells[1][2].
References	- Bai L, et, al. BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo. PLoS One. 2014 Jun 5; 9(6): e99404. - Sun YL, et, al. A novel Bcl-2 inhibitor, BM-1197, induces apoptosis in malignant lymphoma cells through the endogenous apoptotic pathway. BMC Cancer. 2019 Dec 31; 20(1):1.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.